Moderna
MRNA
$2.56 (6.69%)
1D
1W
3M
1Y
5Y
ALL
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Investopedia • 0 hours ago • MRNA
Moderna Stock Jumps Following Bullish Sales View at Healthcare ConferenceSeeking Alpha • 1 day ago • MRNA
Moderna, Inc. (MRNA) Presents at Jefferies London Healthcare Conference (Transcript)Proactive Investors • 3 days ago • MRNA
BioNTech and Moderna at vanguard of new treatment wave - but which is best?CNBC Television • 4 days ago • MRNA
Cramer's Mad Dash: Moderna gets upgrade from HSBCForbes • 7 days ago • MRNA
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.